Historically, many anti-obesity drugs (AOMs) were withdrawn from development and/or market due to safety concerns. Another challenge was that, with few exceptions, most of these AOMs had limited weight loss efficacy. Approved AOMs often do not meet the weight loss expectations of physicians or their patients. Currently, newly approved and investigational AOMs achieve greater weight loss than older AOMs. This has fueled an emerging new challenge of “excess weight loss” with some of these highly effective anti-obesity drugs (heAOM) – something many didn't think was possible before 2020. todaybignews
method
This roundtable review includes the perspectives of 3 obesity experts with experience in the clinical use of AOM. The objective is to provide perspective and guidance in the management of obese patients who experience “excessive weight loss” with heAOM.
result
Panelists generally agreed that before treatment with heAOM, patients with obesity are best informed about the importance of healthy nutrition, adequate hydration, routine physical activity, behavior modification strategies, treatment goals, and expected changes, not just from a therapeutic perspective. From a psychosocial perspective. Although clinicians recognize that the definition of "excess weight loss" can have both objective and subjective considerations, body composition analyzes are often essential to accurately assess adiposity.
Conclusion
The panelists' consensus is reflected in a proposed structured and algorithmic approach to the morbidly obese patient. Once properly assessed, if excessive weight loss due to heAOM hyper-reactivity is determined to be likely, this should prompt the patient (and possibly family and friends) to educate and involve the health and psychosocial aspects of weight loss. A shared decision-making process that determines whether heAOM is best kept at the same dose, dose reduced, temporarily held or, in rare cases, optimally discontinued.
Comments